The PMWC 2021 Microbial Profiling Showcase will provide a 15-minute time slot for selected companies in the Microbiome and Pathogen ID fields. The human microbiome is composed of a wide variety of microorganisms that are essential for maintaining human health and preventing disease. Research in this area is accelerating due to the rapid development in genome sequencing technologies. This showcase will present some of the leading companies in microbial profiling and pathogen identification.
Confirmed Presenting Companies:
Rita R. Colwell is a Distinguished University Professor at the University of Maryland and at the Johns Hopkins University Bloomberg School of Public Health. Colwell’s research interests are focused on global infectious diseases, water and health. She is currently developing an international network to address emerging infectious diseases and water issues, including safe drinking water for both the developed and developing world. Colwell served as the 11th director of the National Science Foundation from 1998 to 2004. Her major interests include K–12 sciences and mathematics education, graduate science and engineering education, and the increased participation of women and minorities in science and engineering. She has held many advisory positions in the U.S. government, nonprofit science policy organizations and private foundations, as well as in the international scientific research community. She is a member of the National Academy of Sciences, the Royal Swedish Academy of Sciences, Stockholm, the Royal Society of Canada, the American Academy of Arts and Sciences, and the American Philosophical Society.
Dr. Foster leads the software engineering, data science, IT operations, and biostatistics teams and guides data strategy. His teams build AI applications that enable and enhance Metabolon’s industry-leading capabilities. He holds a Bachelor of Science in Physics from Duke University and a Ph.D. in Physics from the University of Calgary.
Microbial Profiling Showcase:
Metabolon, the global leader in metabolomics, has a mission to deliver metabolomics data and insights that expand and accelerate the impact of life sciences research. Our industry-leading data helps to address challenging and pressing questions - accelerating research and development success.
Dr. Nur A Hasan is a molecular microbiologist with experiences in microbial genomics, microbiome, bioinformatics and molecular ecology. Dr. Hasan is the Chief Executive Officer of EzBiome Inc., USA. He received his Bachelor and Master’s in microbiology, M.B.A in Marketing and Ph.D. in Microbiology and Genomics. In his multidisciplinary research experience, Dr. Hasan contributed on various independent research projects in the field of infectious communicable diseases and led numerous large-scale genomic, metagenomic and microbiome projects that resulted in multiple patents, 80+ peer-reviewed articles, and over 100 abstracts and conference proceedings on microbiome, biomarker discovery, molecular ecology, and infectious diseases. Dr. Hasan taught numerous webinars and workshops on microbiome and bioinformatics and frequently present his research in scientific conferences nationally and internationally. He is an editorial board member of several scientific journals and continue to serve as ad doc reviewer for 18+ scientific journals.
Microbial Profiling Showcase:
EzBiome is a microbiome company which applies precision microbiome discovery platform to shorten the time for discovery and development of microbiota-based therapeutics and companion diagnostics for microbiome-related diseases.
EzBioCloud – An Advanced Microbiome Platform for Discovery of Exciting New Biology and Transformative Therapeutics!
The microbiome plays a critical role in human health and disease and Bioinformatics is the key to uncover cross-disciplinary microbiome data for novel biomarker discovery, product development, disease dynamics, effects of drugs on the microbiome and vice-versa. The presentation will showcase EzBioCloud Precision Microbiome Discovery Platform and demonstrates how it helps shorten the time for discovery and development of therapeutics and companion diagnostics for microbiome-related diseases.